

# Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes

## Authors

---

Christianne Bourlon,<sup>1\*</sup> Claire Roddie,<sup>2,3\*</sup> Tobias Menne,<sup>4</sup> Jane Norman,<sup>5</sup> Maeve O'Reilly,<sup>2</sup> Adam Gibb,<sup>6</sup> Caroline Besley,<sup>7</sup> Sridhar Chaganti,<sup>8</sup> Carlos Gonzalez Arias,<sup>9</sup> Ceri Jones,<sup>10</sup> Abdalla Dikair,<sup>11</sup> Sharon Allen,<sup>12</sup> Frances Seymour,<sup>13</sup> Wendy Osborne,<sup>4</sup> Amrith Mathew,<sup>8</sup> William Townsend,<sup>2</sup> Piers E. M. Patten,<sup>1,14</sup> Eleni Thoulouli,<sup>5</sup> Ahmed Abdulgawad,<sup>15</sup> Sanne Lugthart,<sup>7</sup> Robin Sanderson,<sup>1</sup> Amy A. Kirkwood<sup>16</sup> and Andrea Kuhn<sup>1</sup>

<sup>1</sup>Department of Hematology, King's College Hospital, London;

<sup>2</sup>Department of Hematology, University College London Hospitals, London;

<sup>3</sup>UCL Cancer Institute, University College London, London;

<sup>4</sup>Department of Hematology, Freeman Hospital, Newcastle University, Newcastle;

<sup>5</sup>Department of Hematology, Manchester Royal Infirmary, Manchester;

<sup>6</sup>Department of Medical Oncology, The Christie Hospital, Manchester;

<sup>7</sup>Department of Hematology, University Hospitals Bristol

and Weston, Bristol; <sup>8</sup>Department of Hematology, Queen Elizabeth Hospital, Birmingham; <sup>9</sup>Department of Hematology, Royal Marsden Hospital, London; <sup>10</sup>Department of Hematology, University Hospital of Wales, Cardiff; <sup>11</sup>Department of Hematology, Queen Elizabeth Hospital, Glasgow; <sup>12</sup>Department of Hematology, Cambridge University Hospitals, Cambridge; <sup>13</sup>Department of Hematology, Leeds Teaching Hospitals, Leeds; <sup>14</sup>Comprehensive Cancer Center, King's College London, London; <sup>15</sup>Department of Hematology, The Christie Hospital, Manchester and <sup>16</sup>CR UK & UCL Cancer Trials Center, UCL Cancer Institute, UCL, London, UK

*\*CB and CR contributed equally as first authors.*

Correspondence:

A. KUHN - andrea.kuhn@nhs.net

<https://doi.org/10.3324/haematol.2024.285010>

## Data Supplement

### Outcomes after chimeric antigen receptor T-cell therapy across large B-cell lymphoma subtypes

**Table S1.** CAR T toxicity across subgroups

Best response	<i>De novo</i> DLBCL N=420	PMBCL N=26	t-FL N=130	t-NFL N=38	p-value <sup>1</sup>	t-MZL N=17	RS N=13	t-other N=8
Grade 3+ CRS	20/420 (4.8%)	3/26 (11.5%)	7/130 (5.4%)	2/38 (5.3%)	0.43	2/17 (11.8%)	0/13 (0%)	0/8 (0%)
Any grade CRS <sup>2</sup>	272/319 (85.3%)	22/26 (84.6%)	75/98 (76.5%)	19/26 (73.1%)	0.11	11/13 (84.6%)	4/6 (66.7%)	4/7 (57.1%)
Grade 3+ ICANS	66/420 (15.7%)	5/26 (19.2%)	21/130 (16.2%)	3/38 (7.9%)	0.55	1/17 (5.9%)	2/13 (15.4%)	0/8 (0%)
Any grade ICANS <sup>2</sup>	132/319 (41.4%)	9/26 (34.6%)	35/98 (35.7%)	5/26 (19.2%)	0.13	2/13 (15.4%)	3/6 (50.0%)	0/7 (0%)
Steroids used	119/274 (43.4%)	9/23 (39.1%)	36/77 (46.8%)	3/19 (15.8%)	0.088	3/13 (23.1%)	0/1 (0%)	0/5 (0%)
Tocilizumab used	199/274 (72.6%)	16/23 (69.6%)	53/78 (68.0%)	11/19 (57.9%)	0.48	7/13 (53.9%)	1/1 (100%)	3/5 (60.0%)
ICU admission	69/244 (28.3%)	7/23 (30.4%)	16/73 (21.9%)	3/18 (16.7%)	0.55	3/13 (23.1%)	0/1 (0%)	0/4 (0%)
Grade 3+ thrombocytopenia 1 month <sup>3</sup>	57/146 (39.0%)	6/17 (35.3%)	26/54 (48.2%)	5/10 (50.0%)	0.59	4/6 (66.8%)	-	1/4 (25.0%)
Grade 3+ neutropenia 1 month <sup>3</sup>	68/145 (46.9%)	7/16 (43.8%)	26/53 (49.1%)	5/9 (55.6%)	0.94	3/5 (60.0%)	-	2/4 (50.0%)
Grade 3+ thrombocytopenia 3 months <sup>3</sup>	9/81 (11.1%)	2/11 (18.2%)	6/37 (16.2%)	2/5 (40.0%)	0.23	1/3 (33.3)	-	1/2 (50.0%)
Grade 3+ neutropenia 3 months <sup>3</sup>	15/81 (18.5%)	2/11 (18.2%)	7/37 (18.9%)	2/5 (40.0%)	0.63	1/3 (33.3)	-	1/2 (50.0%)

<sup>1</sup>Fisher's exact test comparing rates in *de novo* DLBCL/PMBCL/t-FL and t-NFL groups. <sup>2</sup>Any grade: chi-squared for trend 0.13 (CRS), 0.036 (ICANS: lower grades in t-NFL patients,  $p=0.30$  if these patients are excluded). <sup>3</sup>Thrombocytopenia and Neutropenia rates exclude patients who have relapsed by each timepoint.